000128678 001__ 128678
000128678 005__ 20240228145545.0
000128678 0247_ $$2doi$$a10.1111/jphp.12796
000128678 0247_ $$2pmid$$apmid:28872682
000128678 0247_ $$2ISSN$$a0022-3573
000128678 0247_ $$2ISSN$$a0373-1022
000128678 0247_ $$2ISSN$$a2042-7158
000128678 037__ $$aDKFZ-2017-04693
000128678 041__ $$aeng
000128678 082__ $$a610
000128678 1001_ $$aDaaboul, Hamid E$$b0
000128678 245__ $$aβ-2-himachalen-6-ol protects against skin cancer development in vitro and in vivo.
000128678 260__ $$aWallingford, Oxon$$bPharmaceutical Press64910$$c2017
000128678 3367_ $$2DRIVER$$aarticle
000128678 3367_ $$2DataCite$$aOutput Types/Journal article
000128678 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1510056300_26479
000128678 3367_ $$2BibTeX$$aARTICLE
000128678 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128678 3367_ $$00$$2EndNote$$aJournal Article
000128678 520__ $$aPrevious studies in our laboratory showed that Daucus carota oil extract (DCOE) possesses remarkable in-vitro anticancer activity and antitumour promoting effect against DMBA/TPA skin carcinogenesis in mice. Chemical analysis of DCOE led to the isolation of the β-2-himachalen-6-ol (HC), major sesquiterpene with a potent anticancer activity against various colon, breast, brain and skin cancer cells. This study investigated the anticancer activity of HC against invasive epidermal squamous cell carcinoma cells and evaluated its effect in a DMBA/TPA skin carcinogenesis Balb/c murine model.HaCaT-ras II-4 epidermal squamous cells were treated with HC (1, 5, 10, 25 and 50 μg/ml), and cell viability was evaluated with WST 1 assay kit. Cell cycle analysis was carried out by flow cytometry, and pro/anti-apoptotic proteins were measured using Western blot. The effect of topical and intraperitoneal (IP) treatment with HC in mice was assessed using the DMBA/TPA skin carcinogenesis model. Cisplatin (2.5 mg/kg; IP) was used as a positive control. Papilloma incidence, yield and volume were monitored, and isolated papillomas were assessed for their pro/anti-apoptotic proteins and morphology.β-2-himachalen-6-ol showed a dose-dependent decrease in cell survival with an IC50 and IC90 of 8 and 30 μg/ml, respectively. Flow cytometry analysis revealed that treatment with 10 μg/ml HC significantly increased the number of cells undergoing late apoptosis (28%), while 25 μg/ml caused a larger cell shift towards late apoptosis (46.6%) and necrosis (39%). A significant decrease in protein levels of p53 and Bcl-2 and a significant increase in p21 and Bax were observed. Also, there was a significant decrease in p-Erk and p-Akt protein levels. The treatment of mice (IP and topical) with HC caused a significant decrease in papilloma yield, incidence and volume. Similar effects were observed with cisplatin treatment, but HC-treated groups exhibited twofold to threefold increase in survival rates. Similar patterns in the pro- and anti-apoptotic proteins were observed in mice treated with HC, except for a significant increase in p53 protein.In conclusion, HC treatment induced cell cycle arrest (low dose) and promoted apoptosis partly via inhibition of the MAPK/ERK and PI3K/AKT pathways with no significant toxicity to laboratory mice.
000128678 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000128678 588__ $$aDataset connected to CrossRef, PubMed,
000128678 7001_ $$aDaher, Costantine F$$b1
000128678 7001_ $$aTaleb, Robin I$$b2
000128678 7001_ $$aBoulos, Joelle$$b3
000128678 7001_ $$aBodman-Smith, Kikki$$b4
000128678 7001_ $$0P:(DE-He78)c1895aa471c7ac9c7173045464b69b31$$aBoukamp, Petra$$b5$$udkfz
000128678 7001_ $$aShebaby, Wassim N$$b6
000128678 7001_ $$aDagher, Carol$$b7
000128678 7001_ $$aEl-Sibai, Mirvat$$b8
000128678 7001_ $$00000-0003-1572-7133$$aMroueh, Mohamad A$$b9
000128678 773__ $$0PERI:(DE-600)3107-0$$a10.1111/jphp.12796$$gVol. 69, no. 11, p. 1552 - 1564$$n11$$p1552 - 1564$$tJournal of pharmacy and pharmacology$$v69$$x0022-3573$$y2017
000128678 909CO $$ooai:inrepo02.dkfz.de:128678$$pVDB
000128678 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c1895aa471c7ac9c7173045464b69b31$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128678 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000128678 9141_ $$y2017
000128678 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ PHARM PHARMACOL : 2015
000128678 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128678 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128678 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128678 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128678 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128678 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128678 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128678 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128678 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128678 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128678 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128678 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128678 9201_ $$0I:(DE-He78)A110-20160331$$kA110$$lGenetik der Hautkarcinogenese$$x0
000128678 980__ $$ajournal
000128678 980__ $$aVDB
000128678 980__ $$aI:(DE-He78)A110-20160331
000128678 980__ $$aUNRESTRICTED